CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 25 enrolled
Drug / intervention
Perflutren Lipid microspheredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03196076
NCT03196076Phase 2Completed

Contrast-enhanced Ultrasound for Complex Kidney Lesion Diagnosis in Patients With CKD Extension (CEUS CKDx)

University of North Carolina, Chapel Hill·interventional·Posted Jun 22, 2017·Updated Jul 21, 2021

In Brief

A Phase 2 clinical trial evaluating Perflutren Lipid microsphere for Chronic Kidney Diseases and Cystic Kidney Disease. Completed, enrolled 25 participants across 1 site.

Detailed Summary

The purpose of this research study is to evaluate contrast-enhanced ultrasound for kidney malignancies.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJun 22, 2017
Enrollment StartAug 28, 2017
Primary CompletionMar 19, 2021
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 9.0 years ago

Interventions

Perflutren Lipid microspheredrug

Perflutren will be administered in a bolus or continuous infusion using the dosing range and administration type within the perflutren prescribing information.Once perflutren lipid has been administered, the transducer is maintained in a constant position over the area of interest to show the target lesion in order to assess the enhancement pattern during the early, mid and late vascular phases. Images will also be taken of kidney parenchyma in a suitable longitudinal plane.If there are multiple lesions in one subject requiring a second dose, the subject will have the option to undergo a 2nd contrast-enhanced study 30-minutes after the initial contrast dose, per dosing instructions in the package insert.